{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:01:20Z","timestamp":1788210080524,"version":"build-2803163510"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose\/objective<\/jats:title>\n                    <jats:p>Magnetic resonance\u2013linear accelerator (MR-Linac) systems enable high-precision radiotherapy through real-time MR guidance and daily online adaptive treatment planning. While online adaptation offers substantial dosimetric advantages, it extends treatment session durations on an already resource-intensive platform. This study aimed to evaluate patient-reported outcome measures (PROMs) and long-term toxicity profiles associated with MR-guided radiotherapy, with a particular focus on the impact of online adaptive workflows.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This subgroup analysis of an ongoing prospective observational study comprises patients treated with the MRIdian Linac at the Department of Radiation Oncology at Heidelberg University Hospital between January 2019 and May 2021. Online plan adaptation was implemented in February 2020.\u00a0A custom-designed in-house questionnaire (PRO-Q) was employed to assess patient experience with MR-guided treatment. Toxicity was classified according to the Common Terminology Criteria for Adverse Events (CTCAE v. 5.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 231 patients were included, comprising 130 non-adaptive and 101 adaptive treatments across 286 target volumes. Baseline patient characteristics, prior systemic therapy, and median planning target volumes (36.4 mL\n                      <jats:italic>vs<\/jats:italic>\n                      . 35.3 mL) were comparable between groups. Adaptive treatment was associated with significantly prolonged session durations (median 71 minutes\n                      <jats:italic>vs<\/jats:italic>\n                      . 36 minutes; p&amp;lt;0.01). During adaptive treatment, patients reported significantly higher discomfort in domains related to treatment duration, immobility, and sensory perceptions (e.g., tingling) as per PRO-Q responses. No statistically significant differences in overall toxicity were observed. However, patients undergoing adaptive therapy exhibited a faster return to baseline status post-treatment (6\u20138 weeks\n                      <jats:italic>vs<\/jats:italic>\n                      . 6\u201312 months).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Online plan adaptation at the MR-Linac increased treatment times and was associated with less favorable short-term patient-reported outcomes, yet it was delivered safely without compromising toxicity or oncologic outcomes. These results support adaptive MR-guided radiotherapy as a feasible and technically promising approach, while highlighting the need for further studies with validated PROMs and cost-benefit analyses to define its clinical value.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1700649","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:22:44Z","timestamp":1770096164000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term patient experience with online MR-guided radiotherapy: adaptive versus non-adaptive workflow"],"prefix":"10.3389","volume":"16","author":[{"given":"Fabian","family":"Weykamp","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Herder-Wagner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Regnery","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Liermann","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Meixner","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hoegen-Sa\u00dfmannshausen","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Katharina","family":"Renkamp","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Rippke","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Kl\u00fcter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]},{"name":"Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital","place":["Heidelberg, Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Heidelberg","place":["Heidelberg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"H\u00f6rner-Rieber","sequence":"additional","affiliation":[{"name":"Heidelberg Institute of Radiation Oncology (HIRO)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT)","place":["Heidelberg, Germany"]},{"name":"Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Heidelberg","place":["Heidelberg, Germany"]},{"name":"Department of Radiation Oncology, Duesseldorf University Hospital","place":["Duesseldorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121980","article-title":"New approaches in radiotherapy","volume":"17","author":"Webster","year":"2025","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3857\/roj.2020.00976","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience","volume":"39","author":"Ugurluer","year":"2021","journal-title":"Radiat Oncol J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.2012593","article-title":"Online adaptive MR-guided stereotactic radiotherapy for unresectable Malignancies in the upper abdomen using a 1.5 T MR-linac","volume":"61","author":"Daamen","year":"2022","journal-title":"Acta Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/cancers14030716","article-title":"MRI-guided online adaptive stereotactic body radiation therapy of liver and pancreas tumors on an MR-linac system","volume":"14","author":"Stanescu","year":"2022","journal-title":"Cancers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.01.024","article-title":"Feasibility of stereotactic radiotherapy using a 1.5 T MR-linac: Multi-fraction treatment of pelvic lymph node oligometastases","volume":"134","author":"Werensteijn-Honingh","year":"2019","journal-title":"Radiotherapy Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejmp.2020.07.027","article-title":"Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers","volume":"77","author":"Padgett","year":"2020","journal-title":"Physica Medica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13014-021-01813-6","article-title":"Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis","volume":"16","author":"Mayinger","year":"2021","journal-title":"Radiat Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.3390\/cancers13071523","article-title":"Feasibility and early clinical experience of online adaptive MR-guided radiotherapy of liver tumors","volume":"13","author":"Rogowski","year":"2021","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13014-022-02021-6","article-title":"Dosimetric benefit of MR-guided online adaptive radiotherapy in different tumor entities: liver, lung, abdominal lymph nodes, pancreas and prostate","volume":"17","author":"Nierer","year":"2022","journal-title":"Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00066-021-01834-w","article-title":"Stereotactic body radiotherapy of lymph node metastases under MR-guidance: First clinical results and patient-reported outcomes","volume":"198","author":"Weykamp","year":"2022","journal-title":"Strahlentherapie und Onkologie"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.01.038","article-title":"SMART ablation of lymphatic oligometastases in the pelvis and abdomen: clinical and dosimetry outcomes","volume":"168","author":"Regnery","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757031","article-title":"Adaptive MR-guided stereotactic radiotherapy is beneficial for ablative treatment of lung tumors in high-risk locations","volume":"11","author":"Regnery","year":"2021","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100941","DOI":"10.1016\/j.ctro.2025.100941","article-title":"Prospective planning comparison of magnetic resonance-guided vs. internal target volume-based stereotactic body radiotherapy of hepatic metastases - Which patients do really benefit from an MR-linac","volume":"52","author":"Hoegen-Sa\u00dfmannshausen","year":"2025","journal-title":"Clin Trans Radiat Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100567","DOI":"10.1016\/j.ctro.2022.100567","article-title":"Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk","volume":"39","author":"Hoegen","year":"2023","journal-title":"Clin Trans Radiat Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.3390\/cancers14246041","article-title":"Dosimetric benefit of adaptive magnetic resonance-guided stereotactic body radiotherapy of liver metastases","volume":"14","author":"Weykamp","year":"2022","journal-title":"Cancers"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1308406","article-title":"Dosimetric benefit of online treatment plan adaptation in stereotactic ultrahypofractionated MR-guided radiotherapy for localized prostate cancer","volume":"14","author":"Fink","year":"2024","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13014-024-02466-x","article-title":"Intrafraction organ movement in adaptive MR-guided radiotherapy of abdominal lesions - dosimetric impact and how to detect its extent in advance","volume":"19","author":"Buchele","year":"2024","journal-title":"Radiat Oncol (London England)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13014-021-01945-9","article-title":"Operating procedures, risk management and challenges during implementation of adaptive and non-adaptive MR-guided radiotherapy: 1-year single-center experience","volume":"16","author":"Garcia Sch\u00fcler","year":"2021","journal-title":"Radiat Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2018.08.010","article-title":"Magnetic resonance image-guided radiotherapy (MRIgRT): A 4.5-year clinical experience","volume":"30","author":"Henke","year":"2018","journal-title":"Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.610637","article-title":"Magnetic resonance-guided stereotactic body radiotherapy of liver tumors: initial clinical experience and patient-reported outcomes","volume":"11","author":"Weykamp","year":"2021","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"HSI. S11093","DOI":"10.4137\/HSI.S11093","article-title":"Article commentary: patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)","volume":"6","author":"Weldring","year":"2013","journal-title":"Health Serv Insights"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2021.06.003","article-title":"Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac","volume":"30","author":"Barnes","year":"2021","journal-title":"Clin Trans Radiat Oncol"},{"key":"B23","article-title":"Patient-reported outcome measurements on the tolerance of magnetic resonance imaging-guided radiation therapy","volume":"10","author":"Tetar","year":"2018","journal-title":"Cureus"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01782","article-title":"Patient-reported tolerance of magnetic resonance-guided radiation therapy","volume":"10","author":"Sayan","year":"2020","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100224","DOI":"10.1016\/j.tipsro.2023.100224","article-title":"Patient expectation and experience of MR-guided radiotherapy using a 1.5T MR-Linac","volume":"29","author":"de Mol van Otterloo","year":"2024","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"100240","DOI":"10.1016\/j.tipsro.2024.100240","article-title":"Prospective evaluation of patient-reported anxiety and experiences with adaptive radiation therapy on an MR-linac","volume":"29","author":"Moreira","year":"2024","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01603-1","article-title":"Definition and quality requirements for stereotactic radiotherapy: consensus statement from the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery","volume":"196","author":"Guckenberger","year":"2020","journal-title":"Strahlentherapie und Onkologie"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-020-01578-z","article-title":"First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany","volume":"196","author":"Kl\u00fcter","year":"2020","journal-title":"Strahlentherapie und Onkologie"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tipsro.2022.04.005","article-title":"First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac","volume":"22","author":"Janssen","year":"2022","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.05.048","article-title":"MR-guided gated stereotactic radiation therapy delivery for lung, adrenal, and pancreatic tumors: A geometric analysis","volume":"102","author":"van S\u00f6rnsen de Koste","year":"2018","journal-title":"Int J Radiat Oncol Biol Physics"},{"key":"B31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ctro.2020.11.014","article-title":"Marker-less online MR-guided stereotactic body radiotherapy of liver metastases at a 1.5 T MR-Linac \u2013 Feasibility, workflow data and patient acceptance","volume":"26","author":"Gani","year":"2021","journal-title":"Clin Trans Radiat Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1095633","article-title":"Local control and patient reported outcomes after online MR guided stereotactic body radiotherapy of liver metastases","volume":"12","author":"Uder","year":"2023","journal-title":"Front Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.10819","article-title":"Safety and tolerability of online adaptive high-field magnetic resonance\u2013guided radiotherapy","volume":"7","author":"Westerhoff","year":"2024","journal-title":"JAMA network Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.03.052","article-title":"Patient-reported quality-of-life outcomes after abdominopelvic stereotactic body radiation therapy (SBRT) using an MR-linac system","volume":"122","author":"Jooya","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.05.033","article-title":"Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis","volume":"173","author":"Barry","year":"2022","journal-title":"Radiotherapy Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"110702","DOI":"10.1016\/j.radonc.2024.110702","article-title":"Clinical validation of a prognostic preclinical magnetic resonance imaging biomarker for radiotherapy outcome in head-and-neck cancer","volume":"204","author":"Winter","year":"2025","journal-title":"Radiotherapy Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13014-025-02589-9","article-title":"Longitudinal assessment of diffusion-weighted imaging during magnetic resonance-guided radiotherapy in head and neck cancer","volume":"20","author":"Boeke","year":"2025","journal-title":"Radiat Oncol (London England)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging\u2013guided vs computed tomography\u2013guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","volume":"9","author":"Kishan","year":"2023","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13014-020-01604-5","article-title":"Dosimetric effects of adaptive prostate cancer radiotherapy in an MR-linac workflow","volume":"15","author":"Mannerberg","year":"2020","journal-title":"Radiation Oncology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/cancers16020270","article-title":"MR-LINAC, a new partner in radiation oncology: current landscape","volume":"16","author":"Ocanto","year":"2024","journal-title":"Cancers"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-016-1057-y","article-title":"A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer","volume":"22","author":"Shimizuguchi","year":"2017","journal-title":"JIjoco"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial","volume":"12","author":"Nutting","year":"2011","journal-title":"The Lancet Oncology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non\u2013small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00066-024-02358-9","article-title":"MR-linac: role of artificial intelligence and automation","volume":"201","author":"Psoroulas","year":"2025","journal-title":"Strahlentherapie und Onkologie"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phro.2020.12.004","article-title":"Clinical implementation of artificial intelligence-driven cone-beam computed tomography-guided online adaptive radiotherapy in the pelvic region","volume":"17","author":"Sibolt","year":"2021","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.3390\/cancers16061210","article-title":"Clinical workflow of cone beam computer tomography-based daily online adaptive radiotherapy with offline magnetic resonance guidance: the modular adaptive radiotherapy system (MARS)","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16061210","article-title":"Combining CT-based online adaptive radiotherapy with offline MR guidance: the modular adaptive radiotherapy system (MARS)","volume":"16","author":"Weykamp","year":"2024","journal-title":"Cancers"},{"key":"B48","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/jcm13040957","article-title":"Daily AI-based treatment adaptation under weekly offline MR guidance in chemoradiotherapy for cervical cancer 1: the AIM-C1 trial","volume":"13","author":"Weykamp","year":"2024","journal-title":"J Clin Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1700649\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:22:45Z","timestamp":1770096165000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1700649\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":48,"alternative-id":["10.3389\/fonc.2026.1700649"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1700649","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"article-number":"1700649"}}